Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PVX-4
- Development stage
- Phase 1
- Lead developer
- PapiVax Biotech
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PVX-4 is a DNA-based therapeutic vaccine under development by PapiVax Biotech for the treatment of high-grade intraepithelial neoplasias associated with human papillomavirus type 16 (HPV16), including cervical, vaginal, vulvar, and anal intraepithelial neoplasia (CIN2/3, VaIN2/3, VIN2/3, AIN2/3). The vaccine encodes the E6, E7, and L2 genes of HPV16 fused to calreticulin (CRT) as a molecular adjuvant. It is administered intramuscularly using the TriGrid Delivery System. The mechanism of action involves inducing an immune response against HPV16-infected cells to eliminate existing lesions and prevent new infections. Early clinical data suggest high efficacy in viral clearance and resolution of abnormal pathology in patients with HPV16+ lesions. As of early 2025, PVX-4 is in Phase I clinical trials with plans for late-stage testing[1][2][3].
- Other names
- CRTE6E7L2 DNA vaccineCRTE-6E7L2 DNA vaccineCRTE 6E7L2 DNA vaccine
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 L2
Beyond the preview
Go deeper on PVX-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PVX-4.